Immunic (in discussions with Roche) plans to conduct FDA regulatory meetings for two...
Anavex starts dosing patients in Rett syndrome trial
Anavex Life Sciences has dosed the first patient in the Phase II/III EXCELLENCE clinical trial of ANAVEX 2-73 (blarcamesine) for the treatment of Rett syndrome.
Vivoryon develops new Phase IIa Alzheimer’s trial design
Vivoryon Therapeutics has reported updates to its Alzheimer’s Disease clinical development programme being conducted in the US and the EU.
Minerva Neurosciences’ roluperidone fails in Phase III study
Minerva Neurosciences has reported that roluperidone failed to meet endpoints in a Phase III clinical trial for the treatment of negative symptoms in schizophrenia.
Acadia to combine two Phase III trials of pimavanserin in MDD
Acadia Pharmaceuticals has plans to combine Phase III CLARITY-2 and CLARITY-3 clinical trials of pimavanserin for the adjunctive therapy of major depressive disorder (MDD) into one study.
Roche reports additional safety data of satralizumab in NMOSD
Roche has reported new pooled safety data of its satralizumab drug to treat patients suffering from neuromyelitis optica spectrum disorder.
ONGENTYS (opicapone) for the Treatment of Parkinson’s Disease
ONGENTYS® (opicapone) is the first and only approved catechol-O-methyltransferase (COMT) inhibitor indicated for the treatment of Parkinson's disease with off episodes, used as an adjunctive treatment to levodopa and carbidopa.
Idorsia’s insomnia drug daridorexant passes Phase III study
Switzerland-based Idorsia has reported positive top-line data from the Phase III clinical trial of daridorexant for the treatment of insomnia.
Zelira Therapeutics’ cannabis trial meets goals for insomnia
Zelira Therapeutics has reported positive data from the Phase Ia/IIb clinical trial of medicinal cannabis for the treatment of insomnia.
ZEPOSIA (Ozanimod) for the Treatment of Multiple Sclerosis
ZEPOSIA® (Ozanimod) is the only FDA approved sphingosine-1-phosphate (S1P) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in adults.
NURTEC (Rimegepant) for the Acute Treatment of Migraine
NURTECTM (Rimegepant) is the only calcitonin gene-related peptide (CGRP) receptor antagonist indicated for acute treatment of migraine in adults.